We are Healthy
San Francisco

San Francisco Expanded Doxy-PEP Eligibility

The city now allows clinicians to offer post-exposure prophylaxis to cisgender women based on individual risk assessment.

Updated on Oct. 14, 2026 in Sexual Health

Gouache-painted illustration of a glass jar with antibiotic capsules, representing a clinical approach to preventative health and medical access.
San Francisco health officials have expanded eligibility for doxy-PEP to include cisgender women, aiming to further reduce bacterial STI rates. AI Illustration. Upload story photo >

Live Poll

Is expanding antibiotic use for STI prevention a safe approach for your community?

In May 2026, San Francisco health officials updated guidance to allow clinicians to offer doxy-PEP to cisgender women and others assigned female at birth. This policy change follows reports of declining infection rates across the city.

Why it matters

Expanding access to post-exposure prophylaxis is a key strategy for the city to further reduce the incidence of bacterial STIs and prevent cases of congenital syphilis. Officials based this update on medical studies from Japan and Kenya that support the use of doxycycline for this population.

The city policy shift follows published research from Japan and Kenya suggesting doxycycline effectively prevents bacterial STIs in cisgender women. The decision comes after San Francisco saw significant drops in syphilis, chlamydia, and gonorrhea during 2025.

The players

San Francisco Department of Public Health

The local agency responsible for managing disease surveillance and setting city-wide sexual health clinical guidance.

The details

Doxy-PEP involves taking a single 200-milligram dose of doxycycline within 72 hours of sexual activity to help prevent bacterial infections. Clinicians now use shared decision-making to evaluate risk factors for cisgender women, a departure from current CDC recommendations that primarily target gay, bisexual, and other men who have sex with men and transgender women.

Timeline

  1. October 2022: San Francisco issued the nation's first doxy-PEP guidance.

  2. 2024: This year served as the baseline for city infection rate comparisons.

  3. 2025: The city reported measurable drops in syphilis, chlamydia, and gonorrhea.

  4. May 2026: San Francisco officially updated its doxy-PEP eligibility policy.

Health Landscape

This policy change expands upon national CDC doxy-PEP clinical recommendations which are currently limited to men who have sex with men and transgender women. The move reflects a broader effort to adapt bacterial STI prevention strategies for a wider demographic.

If you are concerned about your STI risk, the most important step is to discuss these updated criteria with your primary care provider or a sexual health specialist. Your doctor can help assess your specific risk factors and determine if this prophylactic approach is appropriate for your health history.

The takeaway

Doxy-PEP is now an available tool for a broader segment of the population in San Francisco to help lower the risk of bacterial STIs. Discuss your sexual health history and individual risk profile with your clinician to determine if this preventive strategy is right for you.

Further reading

For more on preventative measures and current standards, visit the Sexual Health section.

Source note: This article includes information reported by Medical Daily.

Live Poll

Is expanding antibiotic use for STI prevention a safe approach for your community?